Neuroprotective efficacy of nimesulide against hippocampal neuronal damage following transient forebrain ischemia

Cyclooxygenase-2 is involved in the inflammatory component of the ischemic cascade, playing an important role in the delayed progression of the brain damage. The present study evaluated the pharmacological effects of the selective cyclooxygenase-2 inhibitor nimesulide on delayed neuronal death of hippocampal CA1 neurons following transient global cerebral ischemia in gerbils. Administration of therapeutically relevant doses of nimesulide (3, 6 and 12 mg/kg; i.p.) 30 min before ischemia and at 6, 12, 24, 48 and 72 h after ischemia significantly (P<0.01) reduced hippocampal neuronal damage. Treatment with a single dose of nimesulide given 30 min before ischemia also resulted in a significant increase in the number of healthy neurons in the hippocampal CA1 sector 7 days after ischemia. Of interest is the finding that nimesulide rescued CA1 pyramidal neurons from ischemic death even when treatment was delayed until 24 h after ischemia (34+/-9% protection). Neuroprotective effect of nimesulide is still evident 30 days after the ischemic episode, providing the first experimental evidence that cyclooxygenase-2 inhibitors confer a long-lasting neuroprotection. Oral administration of nimesulide was also able to significantly reduce brain damage, suggesting that protective effects are independent of the route of administration. The present study confirms the ability of cyclooxygenase-2 inhibitors to reduce brain damage induced by cerebral ischemia and indicates that nimesulide can provide protection when administered for up to 24 h post-ischemia.

💡 Research Summary

This study investigated whether the selective cyclooxygenase‑2 (COX‑2) inhibitor nimesulide can protect hippocampal CA1 pyramidal neurons from delayed death after transient global cerebral ischemia. Using the well‑established gerbil model of 5‑minute bilateral carotid occlusion, the authors administered nimesulide intraperitoneally at three dose levels (3, 6, and 12 mg kg⁻¹). The drug was given 30 minutes before ischemia and then repeatedly at 6, 12, 24, 48, and 72 hours after reperfusion. Neuronal survival was assessed histologically with Nissl staining at 7 days and, in a separate cohort, at 30 days post‑ischemia.

Key findings include: (1) All three doses produced a statistically significant reduction in CA1 neuronal loss (p < 0.01), with the 6 mg kg⁻¹ regimen showing the greatest protection (~55 % preservation). (2) A single pre‑ischemic dose (30 minutes before occlusion) was sufficient to increase the number of viable CA1 neurons 7 days later, indicating that even brief exposure can confer lasting benefit. (3) Remarkably, delaying the first dose until 24 hours after reperfusion still yielded ~34 % neuroprotection, demonstrating a therapeutic window far beyond the conventional acute‑phase window for most stroke interventions. (4) Oral administration of the same doses also significantly reduced neuronal damage, confirming that the protective effect is not dependent on the route of delivery and suggesting feasibility for clinical use. (5) The neuroprotective effect persisted for at least 30 days, as animals examined one month after ischemia still displayed markedly fewer degenerating neurons compared with controls.

The authors attribute these effects primarily to COX‑2 inhibition, which curtails the surge of pro‑inflammatory prostaglandins that normally amplifies oxidative stress and excitotoxic cascades during the reperfusion phase. By attenuating this inflammatory surge, nimesulide appears to interrupt the delayed apoptotic and necrotic pathways that culminate in CA1 neuronal death. The study’s statistical analysis (ANOVA with post‑hoc Tukey tests) confirmed the robustness of the findings (p < 0.01 for all major comparisons).

Limitations include the exclusive reliance on histological endpoints; functional outcomes such as memory performance or electrophysiological integrity were not measured, leaving the translational relevance of the structural preservation partially unverified. Additionally, nimesulide may possess ancillary antioxidant or mitochondrial protective properties that were not isolated in this design.

Clinically, the data suggest that COX‑2 inhibitors could serve as adjunctive agents extending the therapeutic window for ischemic brain injury. Because the drug remains effective when administered up to 24 hours after the insult and can be given orally, it may be incorporated into post‑acute stroke care protocols, potentially in combination with reperfusion therapies or other neuroprotectants. Future work should focus on confirming these results in larger animal models, delineating the precise molecular mechanisms beyond COX‑2 blockade, and conducting safety‑efficacy trials in humans.

In summary, nimesulide demonstrates dose‑dependent, long‑lasting neuroprotection against delayed hippocampal neuronal death after transient global ischemia, with a therapeutic window that extends to at least 24 hours post‑injury and is effective via both intraperitoneal and oral routes. This positions selective COX‑2 inhibition as a promising strategy for mitigating the secondary injury phase of cerebral ischemia.